摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4,7b-triazacyclopenta[cd]inden-2-thiol | 333986-55-3

中文名称
——
中文别名
——
英文名称
1,4,7b-triazacyclopenta[cd]inden-2-thiol
英文别名
2,6,11-triazatricyclo[5.3.1.04,11]undeca-1(10),4,6,8-tetraene-3-thione
1,4,7b-triazacyclopenta[cd]inden-2-thiol化学式
CAS
333986-55-3
化学式
C8H5N3S
mdl
——
分子量
175.214
InChiKey
ALGQEKVQFKBFSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    61.4
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Cyclic amine compounds as CCR5 antagonists
    摘要:
    式(I)的化合物(其中R1是氢原子,可能被取代的碳氢基团,可能被取代的非芳香杂环基团,R2是可能被取代的碳氢基团,可能被取代的非芳香杂环基团,或R1和R2可以彼此结合与A一起形成可能被取代的杂环基团;A是N或N+—R5.Y−(R5是碳氢基团;Y−是一个对离子);R3是可能被取代的环烃基团或可能被取代的杂环基团;n为0或1;R4是氢原子,可能被取代的碳氢基团,可能被取代的杂环基团,可能被取代的烷氧基团,可能被取代的芳基氧基团,或可能被取代的氨基团;E是可能被除氧以外的基团取代的二价脂肪族碳氢基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是亚甲基或氮原子;Q和R中的每一个是键或可能被取代的二价C1-3脂肪族碳氢基团;条件是当G2为OCO时J为亚甲基,当另一个为键时Q和R中的一个不是键,当G1为键时Q和R中的每一个都不被氧基取代)或其盐具有强大的CCR5拮抗活性,并可优势用于治疗或预防人类体内各种HIV引起的传染病(例如艾滋病)。
    公开号:
    US06562978B1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001025200A1
    公开(公告)日:2001-04-12
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物式为(I)(其中R1是氢原子,可被取代的碳氢基团,可被取代的非芳香杂环基团,R2是可被取代的碳氢基团,可被取代的非芳香杂环基团,或R1和R2可以与A一起结合形成可被取代的杂环基团;A是N或N+ -R5 • Y-(R5是碳氢基团;Y-是反离子);R3是可被取代的环烃基团或可被取代的杂环基团;n为0或1;R4是氢原子,可被取代的碳氢基团,可被取代的杂环基团,可被取代的烷氧基,可被取代的芳氧基,或可被取代的基,E是可被除氧基以外的基取代的二价脂肪烃基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团;前提是当G2是OCO时,J是甲基,当另一个是键时,其中一个不是键,当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,并可用于人类各种HIV感染疾病(例如艾滋病)的治疗或预防。
  • Cyclic Amine Compounds as CCR5 Antagonists
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1886994A1
    公开(公告)日:2008-02-13
    A compound of the formula: (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).
    式中的化合物: (其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团,R2 是可被取代的烃基、可被取代的非芳香杂环基团,或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团;A 是 N 或 N+-R5 .Y-(R5 是烃基;Y- 是反阴离子);R3 是可被取代的环烃基或可被取代的杂环基;n 是 0 或 1;R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的基;E 是可被除氧代以外的基团(s)取代的二价脂肪族烃基;G1 是键、CO 或 SO2;G2 是 CO、S02、NHCO、CONH 或 OCO;J 是甲烷或氮原子;Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃;条件是:当 G2 为 OCO 时,J 为甲烷;当另一个为键时,Q 和 R 中的一个不是键;当 Go ils 为键时,Q 和 R 中的每一个没有被氧化基团(s)取代)或其盐具有强效的 CCR5 拮抗活性,可有利地用于治疗或预防人类各种 HIV 感染性疾病(如艾滋病)。例如艾滋病)。
  • CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1220842A1
    公开(公告)日:2002-07-10
  • US6562978B1
    申请人:——
    公开号:US6562978B1
    公开(公告)日:2003-05-13
  • US7348324B2
    申请人:——
    公开号:US7348324B2
    公开(公告)日:2008-03-25
查看更多

同类化合物

3H-1,4,8B-三氮杂苊烯e-3,5(4H)-二酮 2,3,4,5-tetrahydro-1H-pyrido[2',1':2,3]imidazo[4,5-c]azepin-1-one ethyl 2-acetyl-3-(2-hydroxy-6,8-dimethylimidazo[1,2-a]pyridin-3-yl)-3-(methylthio)acrylate 6-ethyl-8-methylpyrido[1,2-a]benzimidazole (7S,8R)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-3-carbonitrile 7-methoxy-1-(3-propynyl)-1,2,3,4-tetrahydropyrido<3',2':4,5>imidazo<1,2-a>pyrimidin-2-one (7R,8S)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 2,4-dimethyl-7,8,9,10-tetrahydro-pyrido[2',3':3,4]pyrazolo[1,5-a]pyrimidine (7R,8S)-4-fluoro-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 1,3-Dihydro-2-methyl-4-methylthio-3-oxo-2H-2,5-diazacyclo<3.2.3>azin 3-(6-{[(3R,5S)-5-(methoxymethyl)pyrrolidin-3-yl]amino}pyrazin-2-yl)imidazo[1,2-a]pyridine-7-carbonitrile 7-hydroxy-3-propylimidazo[1,2-a]pyridine-8-carbonitrile 6-Methyl-9-oxa-1,4a-diaza-fluoren-2-one 8-nitro-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-3-carbonitrile 2,3-dichloro-7-trichloromethyl-imidazo[1,2-a]pyridine Ethyl 4-thiophen-2-ylquinolizin-5-ium-1-carboxylate;bromide 2-methyl-1H-cyclopenta[4,5]imidazo[1,2-a]pyridin-3(2H)-one 2-ethoxycarbonyl-3-oxo-2,3-dihydro-thiazolo[3,2-a]pyridinylium betaine 14a-methyl-9-(pyridin-2-ylethynyl)-2,3,5,6,14,14a-hexahydropyrrolo[2',1':3,4][1,4]diazepino[7,1-b]quinazolin-12(1H)-one 2,9-dimethyl-benzo[1'',2'':4,5;4'',5'':4',5']diimidazo[1,2-a;1',2'-a]dipyridine-6,13-dione 8,9-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-6(7H)-one 6,7-dimethyl-9-propylimidazo[1,5-a]pyrido[3,2-e]pyrazin-2(1H)-one 2-acetyl-4,5-dihydropyrrolo[4,5-g]pyrido[1,2-a]benzimidazole 8-hydroxymethylene-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]benzimidazol-9-one 10-Benzyl-13-propan-2-yl-2,8,11,14-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraen-12-one 2-fluoro-6,9-dimethylpyrido[1,2-a]benzimidazole dipyrido[1,2-a:1',2'-a']benzo[1,2-d:5,4-d]diimidazole-6,13-dione 3-Aethoxycarbonyl-2-amino-1,4-dihydro-8a-aza-acridon 3-bromo-8-chloro-11-[(1-methyl)piperidin-4-yl]-5H,11H-pyrrolo[2,1-c][1,4]benzoxazepine N-((4aR,11bR)-2-amino-3,3,11b-trimethyl-4,4-dioxido-3,4a,5,6,7,11b-hexahydrobenzo[3,4]cyclohepta[1,2-b][1,4]thiazin-10-yl)-6-chloro-3-methylimidazo[1,2-a]pyridine-2-carboxamide 1,3-difluoro-4,9-dimethyl-dipyrido[1,2-a;3',4'-d]imidazole 5-((2-(dimethylamino)ethoxy)imino)pyrido[1',2':1,2]imidazo[4,5-f]isoquinolin-6(5H)-one Dipyrido<1.2-a;1'.2'-c>imidazolium-(10)-bromid 8-(trifluoromethyl)-2,3,4,5-tetrahydro-1H-pyrido[1',2':1,2]imidazo[4,5-d]azepine 3,4-difluoro-1-methoxy-9-methyl-dipyrido[1,2-a;3',4'-d]imidazole benzo[4,5]imidazo[1,2-a]pyridin-6-ylmethanol (7R,8S)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 7-(4-ethyl-1,4-diazepan-1-yl)-3-(8-fluoroimidazo[1,2-a]pyridin-2-yl)-2H-pyrano[2,3-b]pyridin-2-one 2-tert-butyl-8-oxo-7,9-dimethylimidazo<4.5-c>imidazo<1.2-a>pyridine 8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 2,8,12-Triazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene 2-ethylpyrido<1'',2'':1',2'>imidazo<4',5':4,5>imidazo<1,2-c>pyrimidin-1-one 3,4-bis(hydroxymethyl)dipyrido[1,2-a;3',4'-d]imidazole 3-methyldipyrido[1,2-a;3',4'-d]imidazole 2-methyl-6,7,8,9-tetrahydropyrido<1,2-a>benzimidazole 6,7,8,9-tetrahydrobenzo[4,5] imidazo[1,2-a]pyridin-3-amine 3-bromo-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine N-[1-[3-(3-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide N-[1-[3-(2-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide